The invention relates to a pharmaceutical composition in the form of a tablet, comprising a) a crystalline form of bilastine according to polymorph form 2, wherein the crystalline form has characteristic peaks at 6.53, 15.24, 15.86, and 18.07 ?0.2 degrees 2-theta in a powder X-ray diffraction pattern, b) a water-soluble filler, and optionally c) a water-insoluble filler. The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet comprising dry granulation of a blend of the tablet components and compression of the granules to a tablet, or direct compression of a blend to a tablet. The invention relates further to the medical use of the pharmaceutical composition in the treatment of allergic rhino-conjunctivitis and/or urticaria.